Eli Lilly's Lepodisiran Shows Promise in Reducing Genetic Heart Disease Risk Factors

Recent data revealed at an important medical conference highlights that Eli Lilly's lipid-lowering drug, Lepodisiran, significantly reduces levels of lipoprotein(a) (Lp(a)), a key risk factor for genetic heart disease. Published in the New England Journal of Medicine, the mid-stage trial demonstrated a remarkable 93.9% average reduction in Lp(a) levels within six months after a single 400 mg dose, compared to the placebo group. The trial involved 72 patients in the treatment group and 69 in the placebo group, with a subsequent injection after six months leading to an almost 95% reduction in Lp(a) levels over a year. Notably, no serious adverse events related to the drug were reported.

Unlike LDL cholesterol, which can be managed through diet and statins, there are currently no approved therapies targeting Lp(a). Elevated Lp(a) levels significantly increase the risk of heart attacks, strokes, aortic valve stenosis, and peripheral artery disease. Approximately 20% of the global population, or about 1.4 billion people, have elevated Lp(a), with the highest risk observed in the African population. Patients typically rely on statins for controlling other lipid markers, but these do not affect Lp(a).

In the competitive landscape of Lp(a) therapies, Eli Lilly, Novartis, and Amgen are making strides, with Merck also entering the field through licensing agreements. Lepodisiran is administered once a month, while Pelacarsen (by Novartis) has shown an 80% average reduction in Lp(a) levels with an 80 mg/month subcutaneous injection. However, the Phase III clinical data for Pelacarsen has been postponed to mid-2026, raising concerns about its market performance.

Amgen's siRNA therapy, Olpasiran, appears to be a strong competitor, showing over 95% reduction in Lp(a) levels in patients with atherosclerotic cardiovascular disease after every 12 weeks of administration. Results are also expected in 2026.

Novartis's Pelacarsen, an antisense oligonucleotide (ASO), selectively cleaves the mRNA of the LPA gene, effectively reducing Lp(a) synthesis. In its Phase II trial, Pelacarsen significantly lowered Lp(a) levels, with 98% of patients achieving levels below 50 mg/dL. However, it requires more frequent dosing compared to Lepodisiran.

In addition to Lepodisiran, Eli Lilly is concurrently developing an oral small molecule Lp(a) inhibitor, Muvalaplin, creating a dual strategy of injectable and oral therapies to cater to diverse patient needs. Furthermore, on March 25, Merck announced a collaboration with Hengrui Medicine to develop an oral Lp(a) drug, HRS-5346, which could emerge as another potential player in the market.

The success of this collaboration hinges on regulatory approvals and meeting standard transaction conditions, with completion expected in Q2 2025. Overall, the development of Lepodisiran exemplifies the ongoing exploration of cardiovascular targets following the success of PCSK9 inhibitors. Its Phase III trial outcomes could significantly influence the future landscape of lipid-lowering therapies, potentially paving the way for combined PCSK9 and Lp(a) treatment strategies.